Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)

Journal of the American Academy of Dermatology

Volumn 74, Issue 2, 2016, Pages 370-371

  Harris, John E ^a   Rashighi, Mehdi ^a   Nguyen, Nhan ^b   Jabbari, Ali ^b   Ulerio, Grace ^b   Clynes, Raphael ^b   Christiano, Angela M ^b   Mackay Wiggan, Julian ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RUXOLITINIB; SIMVASTATIN; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE;

ADULT; ALOPECIA AREATA; ARTICLE; CASE REPORT; DEPIGMENTATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG WITHDRAWAL; FOLLOW UP; HAIR GROWTH; HAIR LOSS; HUMAN; MALE; PIGMENT DISORDER; PRIORITY JOURNAL; SKIN EXAMINATION; SKIN PIGMENTATION; VITILIGO; COMPLICATION; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HAIR; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; ALOPECIA AREATA; HAIR; HUMANS; MALE; PROTEIN KINASE INHIBITORS; PYRAZOLES; SKIN PIGMENTATION; VITILIGO;

EID: 84950116100     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2015.09.073     Document Type: Article

References (5)

1. 1 Rashighi, M., Agarwal, P., Richmond, J.M., et al. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med, 6, 2014, 223ra23.
2. 2 Xing, L., Dai, Z., Jabbari, A., et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med 20 (2014), 1043–1049.
3. 3 Vannucchi, A.M., Kiladjian, J.J., Griesshammer, M., et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372 (2015), 426–435.
4. 4 Quintás-Cardama, A., Kantarjian, H., Cortes, J., et al. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov 10 (2011), 127–140.
5. 5 Craiglow, B.G., King, B.A., Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy. JAMA Dermatol 151 (2015 Jun 24), 1110–1112.